Instil Bio, Inc. (TIL) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies, including tumor-infiltrating lymphocyte (TIL) cell therapies and in-licensed bispecific antibodies. This report covers the quarterly period ended June 30, 2024. The company is currently executing a strategic restructuring plan (the "2024 Plan") involving the closure of its UK manufacturing facility and the cessation of the ITIL-306 clinical trial to realign operations.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(14.9) million | $(39.2) million | $(75.7) million |
| Loss Per Share (Basic/Diluted) | $(2.29) | $(6.03) | $(11.64) |
| Operating Expenses | $14.1 million | $38.1 million | $79.4 million |
| Cash & Cash Equivalents | $6.8 million | $6.8 million | $22.9 million (end of period) |
| Total Liquid Assets (Cash, Marketable Securities, Long-term Investments) |
$152.6 million | $152.6 million | $164.3 million (end of period) |
| Debt (Loan Payable) | $81.9 million | $81.9 million | $81.4 million |
| Accumulated Deficit | $(620.2) million | $(620.2) million | $(500.6) million |
Material Changes vs. Prior Period
- Significant Expense Reduction: Total operating expenses decreased by approximately 52% year-over-year for the six months ended June 30, 2024 ($38.1M vs. $79.4M). This was driven by a 65% reduction in Research and Development (R&D) expenses and a 79% reduction in Restructuring and Impairment charges.
- Restructuring Charges: The company recorded $4.8 million in restructuring and impairment charges for the six months ended June 30, 2024, compared to $25.6 million in the same period in 2023. The 2024 charges relate primarily to the closure of UK operations and asset impairments.
- Interest Expense Increase: Interest expense increased to $4.0 million for the six months ended June 30, 2024, from $1.2 million in the prior year period, due to higher interest rates on the company's construction loan.
- Cash Flow Improvement: Net cash used in operating activities improved significantly to $25.0 million for the six months ended June 30, 2024, compared to $54.2 million in the prior year period.
Guidance, Outlook, and Recent Developments
- Strategic Pivot: Management continues to execute the 2024 Plan, which includes closing the UK manufacturing facility and clinical trial operations. The company estimates incurring an additional $0.5 million in charges related to this plan by the end of 2024.
- New Collaboration (Subsequent Event): On August 1, 2024, the company's subsidiary SynBioTx in-licensed bispecific antibodies (SYN-2510 and SYN-27M) from ImmuneOnco Biopharmaceuticals. The deal includes a $10 million upfront payment and potential milestones totaling up to $2.1 billion.
- Facility Lease (Subsequent Event): On July 10, 2024, the company leased its Tarzana, California manufacturing facility to AstraZeneca Pharmaceuticals LP for an initial term of 15 years. The lease includes an initial base rent of approximately $7.5 million annually, with rent abatement during the first year.
- Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($152.6 million as of June 30, 2024) are sufficient to fund operations beyond 2026. The company is evaluating a potential sale of the Tarzana facility, which could extend its cash runway.
- Risks: The company faces risks related to its limited operating history, the uncertainty of clinical trial outcomes, reliance on third-party collaborators for manufacturing and trials (particularly in China), and the need for substantial additional funding to achieve profitability.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $152.6 million in liquid assets against the projected burn rate, considering the upcoming $10 million upfront payment for the ImmuneOnco collaboration and potential additional restructuring costs.
- Debt Covenants: Confirm continued compliance with the loan agreement covenants, specifically the requirement to maintain consolidated net worth and liquid assets of at least $85.0 million.
- Restructuring Completion: Monitor the completion of the UK facility closure and the finalization of the 2024 Plan to ensure no unexpected additional charges arise.
- Collaboration Terms: Review the specific terms of the ImmuneOnco agreement, particularly the milestone triggers and royalty rates, to assess future cash outflow obligations.
- Asset Sale Potential: Track the progress of the potential sale of the Tarzana facility, as this transaction is a key variable in extending the company's financial runway.